FDA approval has transformed zilganersen from an experimental antisense programme into the first disease-modifying medicine for Alexander disease. For Ionis Pharmaceuticals, however, ZANVASTRO is also a test of whether years of RNA-targeted neurology research can translate into a sustainable independently commercialized franchise.
The FDA has expanded HYRNUO into first-line advanced HER2-mutated non-small cell lung cancer after a 75% response rate in an early-phase cohort. The approval gives Bayer an important head start, but rival oral therapies and unfinished confirmatory trials mean the long-term treatment hierarchy remains unsettled.
KKR’s agreement to acquire Integer Holdings joins the multibillion-dollar privatisation of Hologic and American Industrial Partners’ purchase of Avanos Medical. The transactions differ substantially, but together they show why specialised medtech manufacturers, platforms and established healthcare franchises remain attractive to private capital even when near-term growth is uneven.
Tempus AI’s FDA-cleared ECG-PH software turns an ordinary 12-lead electrocardiogram into a machine-learning risk signal for pulmonary hypertension. The clinical-performance data show why the technology could be useful for ruling out disease and prioritising follow-up, while also explaining why it cannot replace echocardiography or right-heart catheterisation.
PTC Therapeutics secured Sangamo Therapeutics’ ST-920 Fabry disease programme through a bankruptcy auction for $111 million upfront plus up to $100 million in regulatory milestones. The unusual transaction gives PTC a near-registration gene therapy at a fraction of the cost of many biotechnology acquisitions, but regulatory, manufacturing and commercial risks remain concentrated.
Curium’s agreement to acquire Lantheus Holdings combines a major United States radiodiagnostics franchise with Curium’s global isotope, manufacturing and nuclear-medicine infrastructure. The strategic logic goes well beyond one imaging agent and points toward increasing value being placed on end-to-end radiopharmaceutical capabilities.
ISEMBYLD is not replacing the therapies that transformed spinal muscular atrophy treatment. Scholar Rock is asking physicians and payers to add a muscle-targeted medicine on top of them, creating a commercial proposition that could expand the market while also making reimbursement and treatment logistics central to adoption.
Novartis’ acquisition of Avidity Biosciences brought three late-stage antibody oligonucleotide conjugate programmes into its neuromuscular pipeline. The failure of del-desiran’s Phase 3 HARBOR study now forces investors to separate a damaging lead-asset setback from the value that may remain elsewhere in the platform.
Digital twins and model-informed drug development are moving from research concepts toward regulatory infrastructure, raising the possibility that future pharmaceutical trials could use simulated patients to refine doses, predict outcomes and potentially reduce the number of people required in selected control groups.
Cardiovolt.ai and Imperial College London researchers are developing artificial intelligence capable of extracting hidden signals for heart failure, valve disease and other conditions from routine ECGs, raising the possibility that one of medicine’s oldest tests could become a far broader screening platform.